Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial

CONCLUSIONS: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033.PMID:35918106 | DOI:10.2215/CJN.00550122

Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Daniel W Coyne Ajay K Singh Renato D Lopes Christine K Bailey Tara L DiMino Chun Huang Jeffrey Connaire Anjay Rastogi Sung-Gyun Kim Marcelo Orias Sapna Shah Vickas Patel Alexander R Cobitz Christoph Wanner Source Type: research